Caroline Grönwall

Caroline Grönwall

Senior Forskningsspecialist | Docent
Besöksadress: D2:01, Karolinska Universitetssjukhuset, 17177 Stockholm
Postadress: K2 Medicin, Solna, K2 Reuma Malmström V Grönwall C, 171 77 Stockholm

Om mig

  • I have a strong research interest in adaptive immunity, autoantibodies, and
    autoreactive B cells in health and disease. The translational research
    laboratory is located at the Center for Molecular Medicine and we work in
    close collaboration with the Rheumatology Clinic at Karolinska University
    Hospital. I have a PhD in biotechnology and a background in protein
    engineering at the Royal Institute of Technology (Stockholm, Sweden) and
    pursued my interests in immunology, antibody engineering, and B cell biology
    in rheumatic disease in San Diego (UCSD) and New York (NYU School of
    Medicine) as a postdoctoral researcher and junior faculty 2008-2014. At KI,
    my research team is focusing on understanding the role of autoantibodies and
    autoreactive B cells in rheumatic diseases using approaches including
    generation of human monoclonal autoantibodies for functional in vitro and in
    vivo studies, immunoglobulin repertoire studies, and B cell investigations.
    Contact: caroline.gronwall@ki.se
    Address: /Department of Medicine Solna, Division of Rheumatology, Karolinska
    Institutet, Center for Molecular Medicine (CMM) L8:04, Karolinska University
    Hospital, Visionsgatan 18, 171 64 Stockholm, Sweden. /
    2003 M Sc Engineering Biology, Linköping University, Stockholm,
    Sweden
    2008 PhD Molecular Biotechnology, Royal Institute of Technology (KTH),
    Stockholm, Sweden
    2019 Docent/Associate Professor Experimental Medicine, Karolinska
    Institutet, Stockholm, Sweden

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Swedish Research Council
    1 January 2024 - 31 December 2027
    Autoreactive B cell and antibodies are central in the pathogenesis of rheumatic autoimmune diseases. Distinct autoantibody specificities are the hallmarks of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and idiopathic inflammatory myopathies (myositis). Yet, the autoreactivity is complex and heterogeneous and we still have limited knowledge about what drives the development of autoreactive B cells and how autoantibodies contribute to distinct tissue damage and inflammation. RA is characterized by anti-citrullinated protein autoantibodies (ACPA) and our recent single-cell studies have demonstrated that patient-derived ACPA have unexpected features. They have Fab N-glycosylations, high somatic hypermutations, and multi-reactivity to citrullinated targets, reflecting unusual B-cell processes. Interestingly, some ACPA clones promote pain and bone loss, but some have potent anti-inflammatory properties in murine arthritis. Our clonality data can now be translated into clinical assays for improved patient stratification. In this program I will use an interdisciplinary B-cell pipeline, patient immunomonitoring, and single-cell technology for studies of autoreactive B cells and patient-derived monoclonal autoantibodies. We will obtain in-depth data on the clonal epitope recognition in several diseases and patient subsets. Hereby we will increase the knowledge of fundamental processes in rheumatic disease and contribute to advancing personalized treatment.
  • Swedish Research Council
    1 January 2021 - 31 December 2023
  • Swedish Research Council
    1 January 2014 - 31 December 2018

Anställningar

  • Senior Forskningsspecialist, Medicin, Solna, Karolinska Institutet, 2022-

Examina och utbildning

  • Docent, Experimentell medicin, Karolinska Institutet, 2019

Nyheter från KI

Kalenderhändelser från KI